Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update

NEXT STORY
Clene Nanomedicine Presents Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2021
PREV STORY
CareDx Expands into the Pre-Transplant Kidney Space through TX Connect
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

LONDON, May 11, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM:HCM) (Nasdaq:HCM) ...

author_avatar
NASDAQ Market News

Pluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency

Pluristem expects to begin patient enrollment in the UK in first half of 2017 ...

author_avatar
NASDAQ Market News

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ devimistat (CPI-613®) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Newark, NJ, Jan. 10, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in ...

author_avatar
NASDAQ Market News